5 completed. 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 5 |
Follow Ovarian Carcinosarcoma: new trials by email Literature Review of Ovarian Carcinosarcoma trials Research Report on Ovarian Carcinosarcoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| EPOCH: Eribulin and Pembrolizumab in Ovarian/Uterine Carcinosarcoma Eribulin Mesylate, Pembrolizumab - Ovarian Carcinosarcoma, Uterine Carcinosarcoma | Phase 2 | Completed | Australia New Zealand Gynaecological Oncology Group | 13 | 2023-05-22 | 2026-08-06 |
| Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) Paclitaxel, TAK228 - Ovarian Cancer, Ovarian Neoplasms | Phase 2 | Completed | Imperial College London | 134 | 2018-09-21 | 2024-09-20 |
| Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer Bevacizumab, Temsirolimus - Adult Hepatocellular Carcinoma, Advanced Adult Hepatocellular Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 252 | 2009-09-08 | 2019-01-25 |
| Study of Bevacizumab Followed by Bevacizumab Consolidation for Ovarian Cancer Avastin, Paclitaxel, Cisplatin - Advanced Ovarian Carcinoma, Primary Peritoneal Carcinoma | Phase 2 | Completed | University of Oklahoma | 20 | 2007-07-01 | 2017-07-02 |
| Ziv-aflibercept in Treating Patients With Locally Advanced, Unresectable, or Metastatic Gynecologic Soft Tissue Sarcoma ziv-aflibercept - Fallopian Tube Cancer, Female Reproductive Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 63 | 2006-09-01 | 2015-12-07 |
Fallopian Tube Neoplasms (3) · Ovarian Neoplasms (3) · Carcinoma, Hepatocellular (1) · Carcinoma, Ovarian Epithelial (1) · Somatostatinoma (1)
Adnexal Diseases (4) · Endocrine Gland Neoplasms (4) · Endocrine System Diseases (4) · Female Urogenital Diseases (4) · Female Urogenital Diseases and Pregnancy Complications (4) · Genital Diseases (4) · Genital Diseases, Female (4) · Genital Neoplasms, Female (4) · Gonadal Disorders (4) · Neoplasms (4) · Neoplasms by Site (4) · Ovarian Diseases (4) · Urogenital Diseases (4) · Urogenital Neoplasms (4) · Fallopian Tube Diseases (3)
Bevacizumab (2) · Paclitaxel (2) · Cisplatin (1) · Disulfides (1) · Immunoglobulin G (1) · Sirolimus (1) · aflibercept (1) · eribulin (1) · pembrolizumab (1) · sapanisertib (1) · temsirolimus (1)
National Cancer Institute (NCI) (2) · Australia New Zealand Gynaecological Oncology Group (1) · Imperial College London (1) · University of Oklahoma (1)
Canada (3) · United States (3) · United Kingdom (2) · Australia (1) · Germany (1)
Amit Oza (1) · Clare Scott, AM MB BS PhD (1) · D. Scott McMeekin, MD (1) · Henry Pitot (1) · Jonathan Krell (1)
PMID 25318437, PMID 25488966, PMID 34986897, PMID 35382842, PMID 37702588
N01CM62201 (2), N01CM62203 (2), N01CM62209 (2), N01CM00032 (1), N01CM00038 (1), N01CM00039 (1), N01CM00070 (1), N01CM00071 (1), N01CM00099 (1), N01CM00100 (1), N01CM62204 (1), N01CM62205 (1), N01CM62206 (1), N01CM62207 (1), N01CM62208 (1)